As part of our ongoing aim to bring you reports of new developments, we have added a review of the final comparative analysis of ALPINE, which consolidates the superiority of zanubrutinib over ibrutinib in patients with R/R CLL/SLL, with persistent and durable efficacy and safety advantages.
Independent commentary for the review has been provided by Philip Thompson, Associate Professor of Haematology in the Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia, and a Clinical Haematologist at The Peter MacCallum Cancer Centre and Royal Melbourne Hospitals in Melbourne, Australia.
Please login below to download this issue (PDF)